MNK - Mallinckrodt plc

NYSE - NYSE Delayed Price. Currency in USD

Mallinckrodt plc

3 Lotus Park
The Causeway
Staines-Upon-Thames TW18 3AG
United Kingdom
44 17 8463 6700
http://www.mallinckrodt.com

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Full Time Employees3,700

Key Executives

NameTitlePayExercisedYear Born
Mr. Mark Christopher TrudeauPres, CEO & Director4.04MN/A1961
Dr. Frank ScholzExec. VP and Chief Operations & Digital Innovation Officer1.13MN/A1969
Dr. Steven J. RomanoExec. VP & Chief Scientific Officer1.28MN/A1959
Mr. Mark J. CaseyGen. Counsel1.08MN/A1963
Mr. George A. Kegler Jr.Exec. VP871.12kN/A1956
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Mallinckrodt plc, together with its subsidiaries, develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies in the United States, Europe, the Middle East, Africa, and internationally. It operates in two segments, Specialty Brands, and Specialty Generics and Amitiza. The company markets branded pharmaceutical products for autoimmune and rare diseases in the areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products. It offers H.P. Acthar Gel, an injectable drug for rheumatoid arthritis, multiple sclerosis, infantile spasms, systemic lupus erythematosus, polymyositis, and others; Inomax, a vasodilator to enhance oxygenation and reduce the need for extracorporeal membrane oxygenation; Ofirmev, an intravenous formulation of acetaminophen for pain management; and Therakos photopheresis, an immunotherapy treatment platform. The company is also developing Terlipressin for the treatment of hepatorenal syndrome; StrataGraft, which is in Phase III and II clinical development for the treatment of burns; Stannsoporfin, a heme oxygenase inhibitor for the treatment of jaundice; Xenon gas for inhalation; MNK-6105 and MNK-6106, an ammonia scavenger for the treatment of hepatic encephalopathy, a neuropsychiatric syndrome associated with hyperammonemia; VTS-270 that is in Phase III development for Niemann-Pick Type C, a neurodegenerative disease; and CPP-1X/sulindac, which is in Phase III development for Familial Adenomatous Polyposis. It markets its branded products to physicians, pharmacists, pharmacy buyers, hospital procurement departments, ambulatory surgical centers, and specialty pharmacies. Mallinckrodt plc has collaboration with the Washington University School of Medicine and Silence Therapeutics plc. The company was founded in 1867 and is based in Staines-Upon-Thames, the United Kingdom.

Corporate Governance

Mallinckrodt plc’s ISS Governance QualityScore as of July 29, 2019 is 8. The pillar scores are Audit: 10; Board: 7; Shareholder Rights: 2; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.